[8-K] Qualigen Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Qualigen Therapeutics, Inc. announced several board changes effective November 17, 2025. The Nominating and Governance Committee appointed Koti Meka, the Company’s Chief Financial Officer who also serves as CFO of Faraday Future Intelligent Electric Inc., as an Executive Director. The Committee also named Jie Sheng, Head of Operations & Finance Director of FF Global Partners LLC, as Chairman of the Board of Directors.

On the same date, Chad Chen, already a board member, was appointed to the Board’s Audit Committee. The Company states there are no compensation arrangements, plans, or agreements entered into with the newly appointed board members. Directors Graydon Bensler and Braeden Lichti resigned from the Board, and their resignations were noted as not resulting from any disagreements regarding the Company’s operations, policies, or practices.

Insights

Corporate governance analyst

Board reshuffle adds finance and legal depth, with neutral impact.

The company is concentrating more responsibility in individuals with significant finance and operations backgrounds. Appointing CFO Koti Meka as an Executive Director and Jie Sheng as Chairman brings experience from automotive, energy, and mobility-related organizations directly into board leadership. This may influence strategic oversight and financial discipline, but the filing does not describe any specific strategic shift tied to these changes.

Adding Chad Chen, a practicing attorney, to the Audit Committee increases legal and compliance expertise in a key oversight role, which can be important for disclosure and risk management. The resignations of Graydon Bensler and Braeden Lichti are stated to be unrelated to disagreements on operations or policies, suggesting an orderly transition rather than a governance dispute. Future company filings may clarify how the reconstituted board shapes strategy and committee work.

false 0001460702 0001460702 2025-11-17 2025-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 17, 2025

AIxCrypto Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37428		26-3474527
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5857 Owens Avenue, Suite 300, Carlsbad, California 92008

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code (760) 452-8111

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock (par value $0.001 per share)		QLGN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Director Appointments

On November 17, 2025, the Nominating and Governance Committee (the “Committee”) of Qualigen Therapeutics, Inc. (the “Company”) appointed Koti Meka as an Executive Director of the Company.

Mr. Meka, age 55, serves as the Chief Financial Officer of both the Company and Faraday Future Intelligent Electric Inc., where he has managed finance operations, led financial planning and analysis, and supported initiatives in process improvement, target setting, and cost reduction. Previously, Mr. Meka spent 14 years at Ford Motor Company in various roles focused on cost optimization, product development finance, and corporate finance. His experience also includes work as a Management Consultant at Accenture and as a Product & Application Engineer at Detroit Diesel. Mr. Meka holds an MBA from the University of Michigan-Dearborn, an M.S. in Mechanical Engineering from Wayne State University, and a B.Tech. in Mechanical Engineering from Jawaharlal Nehru Technological University, India.

Further, on November 17, 2025, the Committee appointed Jie Sheng as Chairman of the Board of Directors (the “Board”) of the Company.

Mr. Sheng, age 42, serves as the Head of Operations & Finance Director of FF Global Partners LLC. Previously, Mr. Sheng served as Deputy Managing Director of China Aviation Fuel (Europe) Limited, a wholly-owned subsidiary of China Aviation Oil (Singapore) Corporation (“CAO”), a Singapore Exchange-listed Company, which in turn is a majority-owned subsidiary of China National Aviation Fuel Group Corporation (“CNAF”), a Fortune 500 company, the largest Chinese state-owned aviation fuel supplier which integrates the purchase, transportation, storage, quality management, sales and into-plane service of aviation fuel in China.

There are no compensation arrangements, plans, or agreements entered into between the Company and the newly appointed Board members of the Company.

Committee Appointments

Also, on November 17, 2025, the Committee appointed Chad Chen as a member of the Board’s Audit Committee.

Mr. Chen, age 42, serves as a board member of the Company and as a board member of Faraday Future Intelligent Electric Inc. Mr. Chen is a partner with the law firm of Yoka | Smith, LLP (“Yoka Smith”), where he has practiced since 2012. He represents national and multinational clients in both litigation and non-litigation matters. Mr. Chen’s litigation practice includes representing corporate clients in commercial and business disputes, product liability defense, and class action defense. His non-litigation practice encompasses contract management, counseling on business transactions and serving as outside general counsel in dealing with local, state, and federal agencies, including the U.S. Department of the Treasury, the U.S. Department of Commerce, United States International Trade Commission, and various tax authorities. Prior to joining Yoka Smith, Mr. Chen worked in-house at an alternative energy company and was an associate with Collins + Collins, LLP (formerly Collins Collins, Muir + Stewart LLP). He received his Juris Doctor degree from Southwestern Law School in Los Angeles, California and his Bachelor of Arts in Economics and Political Science from the University of California, Irvine.

Director Resignations

Effective November 17, 2025, Graydon Bensler and Braeden Lichti resigned as members of the Board. These resignations were not a result of any disagreements with the Company on any matter relating to the Company’s operations, policies, or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 20, 2025	AIxCRYPTO HOLDINGS, INC.
	By:	/s/ Kevin A. Richardson II
	Name:	Kevin A. Richardson II
	Title:	Co-Chief Executive Officer

FAQ

What board changes did Qualigen Therapeutics (QLGN) announce on November 17, 2025?

On November 17, 2025, the Company appointed Koti Meka as an Executive Director, Jie Sheng as Chairman of the Board, and added Chad Chen to the Audit Committee, while Graydon Bensler and Braeden Lichti resigned as directors.

Who is Koti Meka and what is his new role at Qualigen Therapeutics (QLGN)?

Koti Meka, age 55, is the Chief Financial Officer of both the Company and Faraday Future Intelligent Electric Inc. He was appointed as an Executive Director of Qualigen Therapeutics by the Nominating and Governance Committee.

Who is the new Chairman of the Board at Qualigen Therapeutics (QLGN)?

Jie Sheng, age 42, who serves as Head of Operations & Finance Director of FF Global Partners LLC and previously held senior roles at China Aviation Fuel (Europe) Limited, was appointed as Chairman of the Board.

What committee change involved Chad Chen at Qualigen Therapeutics (QLGN)?

Chad Chen, already a board member and a partner at law firm Yoka | Smith, LLP, was appointed as a member of the Board’s Audit Committee effective November 17, 2025.

Which directors resigned from the Qualigen Therapeutics (QLGN) board and why?

Graydon Bensler and Braeden Lichti resigned as members of the Board effective November 17, 2025. Their resignations were stated as not due to any disagreements with the Company on operations, policies, or practices.

Are there new compensation arrangements for the newly appointed board members at Qualigen Therapeutics (QLGN)?

The Company states there are no compensation arrangements, plans, or agreements entered into between the Company and the newly appointed Board members in connection with these appointments.